

ASX/Media Release

Immutep Appoints Lucy Turnbull as Non-Executive Director

SYDNEY, AUSTRALIA – 25 February 2022 – [Immutep Limited](#) (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company") is pleased to announce the appointment of Lucy Turnbull AO as Non-executive Director of Immutep, effective immediately.

Ms Turnbull rejoins Immutep's Board having previously served as its Chairman from October 2010 to November 2017, stepping down from the role only due to her elevated professional and personal commitments at the time. Since then Ms Turnbull has remained close to the Company and following the recent tragic passing of Grant Chamberlain, has agreed to replace him as Non-Executive Director.

Ms Turnbull is a distinguished Australian businesswoman, philanthropist and former local government politician. With a background in commercial law and investment banking, she was the first female Lord Mayor of the City of Sydney from 2003 to 2004 and has served on the boards of the NSW Cancer Institute, the Sydney Children's Hospital Foundation, the Sydney Cancer Centre and the Sydney Festival.

In 2011, Ms Turnbull was appointed an Officer of the Order of Australia for her service to the community, local government and business, including through her philanthropic contributions and fundraising for a range of medical, social welfare, educational, youth and cultural organisations. From 2015 to 2020 she served as the inaugural Chief Commissioner of the Greater Sydney Commission, a NSW state government body focused on delivering strategic planning for the whole of metropolitan Sydney.

"It is a pleasure to welcome Lucy back to the Immutep Board," said Chairman Dr Russell Howard. "The Company is at an incredibly exciting juncture given its clinical results in multiple cancer indications and growing global recognition as the leader in LAG-3 immuno-therapy. With Lucy's business acumen, passion for innovative cancer treatments and extensive knowledge of the Company, her contribution will be wide reaching and most valued."

"As a shareholder and longstanding supporter, I have followed Immutep closely in the intervening years and it has been marvellous to see so much achieved by the talented team who I am delighted to be working with again. Immutep is an exceptionally promising biotech with innovative technology that could deliver a meaningful benefit to many cancer patient groups around the world," said Lucy Turnbull.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Immutep's current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep's large pharmaceutical partners.

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Further information can be found on the Company's website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

This announcement was authorised for release by the Board of Immutep Limited.